El-Masry Samir, El-Sayed Ibrahim H, Lotfy Mahmoud, Mahmoud Lamiaa, El-Naggar Mohamed
Molecular and Cellular Biology Department, Genetic Engineering and Biotechnology Research Institute, Minufiya University, Sadat City, Minufiya, Egypt.
J Immunoassay Immunochem. 2007;28(2):91-105. doi: 10.1080/15321810701209738.
Carcinoembryonic antigen (CEA) is the most widely used clinical tumor marker. CEA immunoassay has found acceptance as a diagnostic adjunct in clinical diagnosis of gastrointestinal tumors (GIT). Several immunoassays have been established for detection of CEA in plasma, serum, tissue, feces, and urine of cancer patients using polyclonal or monoclonal antibodies raised against CEA. Some of these assays display both high sensitivity and specificity for the detection of CEA. However, these assays require special and highly expensive equipment and the procedures require long periods for their completion. In the present study, we established a Slot-Blot Enzyme Linked Immunosorbent Assay (SB-ELISA), based on anti-CEA monoclonal antibody (CEA-mAb), as a new, simple, fast, cheap, and non-invasive immunodiagnostic technique for detection of CEA in the urine of GIT patients. Urine and serum samples were collected from 248 GIT patients (58 with pancreatic cancer, 20 with hepatoma, 23 with ampullary carcinoma, 15 with hilar cholangiocarcinoma, 28 with gastric cancer, 14 with esophageal cancer, and 90 with colorectal cancer). Moreover, urine and serum samples were collected from 50 healthy individuals to serve as negative controls. The traditional ELISA technique was used for determination of CEA in the sera of GIT patients using anti-CEA monoclonal antibody. A comparison between the results of both techniques (ELISA and SB-ELISA) was carried out. The traditional ELISA detected CEA in the sera of 154 out of 248 GIT patients with a sensitivity of 59.8%, 51.7% positive predictive value (PPV) and 75.37% negative predictive value (NPV). In addition, it identified 15 false positive cases out of 50 healthy individuals with a specificity of 70%. The urinary CEA was identified by a Western blotting technique and CEA-mAb at a molecular mass of 180 Kda. The developed SB-ELISA showed higher sensitivity, specificity, PPV, and NPV (70.1%, 78%, 62.4%, and 82.13%, respectively) for detection of CEA in the urine of GIT patients. The semi-quantitative SB-ELISA showed a higher overall efficiency of 72.8% versus 63.4% in the case of the quantitative ELISA, for detection of CEA. In conclusion, SB-ELISA is more efficient for detection of CEA in gastrointestinal tumors. It is a simple, rapid, non-invasive, and sensitive assay. Moreover, all steps of the SB-ELISA are performed at room temperature, without the use of expensive equipment; this may enhance the application of this assay in field studies and mass screening programs.
癌胚抗原(CEA)是临床上应用最广泛的肿瘤标志物。CEA免疫测定已被认可为胃肠道肿瘤(GIT)临床诊断中的辅助诊断方法。已经建立了几种免疫测定方法,使用针对CEA产生的多克隆或单克隆抗体来检测癌症患者血浆、血清、组织、粪便和尿液中的CEA。其中一些测定方法对CEA的检测具有高灵敏度和特异性。然而,这些测定方法需要特殊且昂贵的设备,并且程序完成需要很长时间。在本研究中,我们基于抗CEA单克隆抗体(CEA - mAb)建立了一种斑点印迹酶联免疫吸附测定法(SB - ELISA),作为一种用于检测GIT患者尿液中CEA的新的、简单、快速、廉价且非侵入性的免疫诊断技术。收集了248例GIT患者(58例胰腺癌、20例肝癌、23例壶腹癌、15例肝门胆管癌、28例胃癌、14例食管癌和90例结直肠癌)的尿液和血清样本。此外,收集了50名健康个体的尿液和血清样本作为阴性对照。使用抗CEA单克隆抗体的传统ELISA技术用于测定GIT患者血清中的CEA。对两种技术(ELISA和SB - ELISA)的结果进行了比较。传统ELISA在248例GIT患者中的154例血清中检测到CEA,灵敏度为59.8%,阳性预测值(PPV)为51.7%,阴性预测值(NPV)为75.37%。此外,在50名健康个体中识别出15例假阳性病例,特异性为70%。通过蛋白质印迹技术和CEA - mAb鉴定尿液中的CEA分子量为180 Kda。所开发的SB - ELISA在检测GIT患者尿液中的CEA时显示出更高的灵敏度、特异性、PPV和NPV(分别为70.1%、78%、62.4%和82.13%)。半定量SB - ELISA在检测CEA方面的总效率为72.8%,而定量ELISA为63.4%。总之,SB - ELISA在检测胃肠道肿瘤中的CEA方面更有效。它是一种简单、快速、非侵入性且灵敏的测定方法。此外,SB - ELISA的所有步骤均在室温下进行,无需使用昂贵设备;这可能会增强该测定方法在现场研究和大规模筛查项目中的应用。